 Dicerna Pharmaceuticals Nasdaq: DRNA is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about 3.3 billion, shares in cash of 38.25 each. Both the Board of Directors of Novo Nordisk and Dicerna Pharmaceuticals unanimously approved this transaction. 